Indian-origin pharmaceutical research expert Ranjita Shegokar has been appointed as the chief pharma innovation officer at DiHeSys Digital Health Systems GmbH, a germany-based digital healthcare provider.
In her role, Shegokar will be incharge of leading the creation of tailored 2D/3D printed drug delivery systems to meet individual patient needs. An emerging technology in the healthcare industry, 3D-printing is used to manufacture a variety of medicinal products, such as immediate-release tablets, controlled-release tablets, dispersible films, and many more.
Shegnkar's work focuses on precise dosages, targeted therapy, and unique drug combinations, especially for complex conditions like cardiovascular conditions, cancer and pediatric diseases where standard treatments may not be effective due to multiple side effects.
The India-born researcher has an extensive background in pharmaceutical R&D, formulation development and nanoparticle innovations. Her previous breakthrough research has already won many notable awards, such as the German Medical Award 2023 and Deutsche Innovation Prize 2022.
Shegokar acknowledged the challenges of her new position, which include the unique registration and filing process for 3D-printed medicinal innovations, as well as the fact that intellectual property rights, drug regulations, and other policies or regulations are still emerging at the FDA and EMA.
However, she believes with continuous innovation efforts, the future of the 3D-printed drug industry is promising and will certainly be an intelligent way to proceed and personalize the complete therapy, and drug dosing without generating unnecessary chemical and packaging medicine waste. "Right now traditional minds might not believe in 3D printed medicines but I am sure soon it will be a reality, " she said.
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login